Sun Pharma is officially experiencing its moment of glory. The Indian giant has shed its label of “low-cost supplier” to strategically pivot towards high value specialty products. Despite some regulatory obstacles and sustained R&D expenses, the strategy is clearly paying off.
For the very first time, exports rose to $30.47 billion, up 9.4% from the previous year ($27.85 billion), according to the Indian Ministry of Commerce and Industry. The United States remains the main customer, absorbing nearly $9 billion in exports, with a massive market share of 14.29%.
As the global market is expected to grow from $1.6 trillion to $2.3 trillion by 2030 according to a report by Grand View Research, India is quickly moving away from its role as a low-cost generic supplier.
Leading the way is Sun Pharmaceutical Industries Ltd, a national titan that is reinventing itself. The company spent the year transforming into a global leader in specialty products, setting the pace for the future of healthcare in India. This shift has resulted in double-digit profit growth for the fiscal year.
Financial results improvement
Sun Pharma achieved a total revenue of INR 520.4 billion, a 9% increase from the INR 477.6 billion recorded in the 2024 fiscal year. The net profit is even more impressive, with an adjusted net profit reaching INR 119.8 billion, a 19% year-on-year increase. This momentum was driven by its Global Specialty division, which is emerging as a major growth driver.
The domestic Indian market remains dominant, accounting for 33% of total activity. Sales reached INR 169.2 billion, up 13.7% year-on-year from INR 148.9 billion last year. Business in the United States contributed 31% to the mix, with sales of INR 162.4 billion, showing a steady 3.6% year-on-year growth.
Ilumya, the company’s drug used to treat moderate to severe plaque psoriasis in adults, generated $681 million in global sales for the 2025 fiscal year. Additionally, the active pharmaceutical ingredients (API) segment and other revenues increased by 11% year-on-year to reach INR 21.29 billion.
Growth potion
Sun Pharma backed up its R&D efforts during the 2025 fiscal year. The company invested INR 32.48 billion in its laboratories, a steady 2.2% increase from the INR 31.78 billion spent in 2024.
Approximately 40% of this overall R&D budget was allocated to the Global Specialty division and the innovation pipeline. Sun Pharma currently has 116 generic drug applications (ANDA) and 14 new drug applications (NDA) pending approval by the US FDA. Despite this massive investment in future innovation, the recent stock performance has seen a slight slowdown compared to its historical highs.
Upside potential?
Trading at INR 1,652.20, the price actually reflects a decline of about 3.1% over the past 12 months, moving away from its 52-week high of INR 1,851.20. Although the market capitalization reaches the staggering figure of INR 3,900 billion (42.4 billion dollars), the valuation seems surprisingly moderate.
With an average target price of INR 1,956.28, an increase potential of 18% is possible; some analysts even believe it could soar by 44% to reach INR 2,392.00. Trading at 34.1 times its forecasted earnings for the 2026 fiscal year, the stock is slightly cheaper than its three-year average of 35.5 times.
Furthermore, market specialists are optimistic: out of 36 analysts covering the stock, 32 have issued a buy rating.
Possible side effects
The new reciprocal American tariffs of 26% are a real headache. As Sun Pharma heavily relies on patent-protected specialty drugs like Ilumya, it is much more exposed to these costs than its peers focused on generics. Persistent rumors suggest a potential $12 billion deal for American company Organon & Co., although management has officially described this information as “speculative.” Taking on such debt – in addition to Organon’s existing $8.9 billion liability – could disrupt Sun’s reputation for conservative management and excess cash.
Add to that the ongoing compliance difficulties with the USFDA in manufacturing facilities, and you have a journey that could prove tumultuous.
